Team
Management
Govert J. Schouten, Ph.D.
Chief Executive Officer
Dr. Govert Schouten is Chief Executive Officer. He joined Mucosis in May of 2008. Prior to that, Dr. Schouten served as Vice President of Business Development at Crucell. He worked at Crucell for almost 12 years, and was responsible for the global vaccine business development activities. He holds a Ph.D. in virology from Leiden University, The Netherlands.
Thomas Johnston
Chief Business Officer
Mr. Thomas Johnston is Chief Business Officer. In this role he has global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.
Cornelis J. Leenhouts, Ph.D.
Chief Scientific Officer
Dr. Kees Leenhouts is co-founder and Chief Scientific Officer. Previously, Dr. Leenhouts was program manager at Biomade Technology Foundation, and responsible for intranasal vaccine technology development. He spent two years as research fellow at the International Centre for Genetic Engineering and Biotechnology in Trieste, Italy. Dr. Leenhouts is inventor of the Mimopath® technology. He holds a Ph.D. in biology from the University of Groningen.
Roberto Grimaldi
Chief Medical Officer
Dr. Grimaldi is Chief Medical Office. Dr. Grimaldi is an accomplished executive and consultant to the vaccine industry who brings over 25 years of experience. As an expert on vaccine development he will lead the Mucosis development programs into clinical trials in the near future.
Jolande Schoemaker
QA Director
Ms. Schoemaker has been an independent consultant acting as head of Quality Affairs and Qualified Person for Mucosis since 2007. Prior to her work with Mucosis, she was Head of Quality at Crucell (2001-2007) and also a founder of MicroSafe (1993-2001). Ms. Schoemaker studied Pharmacy at the Univeristy of Groningen, the Netherlands and Specialization clinical Pharmacy at Slotervaartziekenhuis, Amsterdam (1979-1982).
Supervisory Board
John Lambert
Chairman of the supervisory board
In a career spanning some 35 years, John has held various Chairman, CEO, President and Board positions in public and private life-science companies in the U.K., the U.S., Europe and major international countries. This includes Presiding over such companies as Aventis Pasteur MSD and Chiron Vaccines. During his career John has always set out to implement strategies to dramatically improve the performance and profitability of his companies. John has also been the elected representative of the global vaccine industry on international Boards promoting immunisation and healthcare worldwide. .
Barry C. Buckland
Member of the supervisory board
PhD in Biochemical Engineering at University College London obtained in 1974. Joined the Merck Research Laboratories (MRL) in 1980 and built a world class Bioprocess R&D group. Leader of process development of all biologically made product candidates within the MRL pipeline and manufacture of Clinical Supplies during the past 20 years. Products developed within this timeline include MEVACOR®, ZOCOR®, IVOMEC®, CANCIDAS®, RECOMBIVAX HB®, VAQTA®, VARIVAX®, COMVAX®., ROTATEQ® (Rotavirus vaccine), ZOSTAVAX® (shingles vaccine) and GARDASIL® (HPV vaccine).
Willem Hazenberg Ph.D.
Member of the supervisory board
Dr. Hazenberg served as chairman of the supervisory board since August 2007. He is partner at BioGeneration Ventures B.V., an early stage Life Sciences venture capital fund with a focus on The Netherlands. He has entrepreneurial experience in creating and working with a large number of start-up companies in the sector.
Otto H. Postma M.Sc.
Member of the supervisory board
Mr. Postma served as member of the supervisory board since August 2007. He is senior investment manager at MedScience Capital B.V. He co-founded (the predecessor of) Pharming Group N.V., founded and managed Pharming Healthcare, Inc., and was instrumental in the establishment or early development of several Dutch life sciences start-ups.
Annemieke J. Wouterse drs. RC
Member of the supervisory board
Ms. Wouterse served as member of the supervisory board since September 2010. She is senior investment manager at N.V. NOM, Investment and Development Company for the Northern Netherlands. She has a financial background and is involved with several highly innovative companies in the region.